Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 589.39 Billion KRW | -12.82% |
| 2022 | 676.1 Billion KRW | 10.0% |
| 2021 | 614.62 Billion KRW | -0.11% |
| 2020 | 615.3 Billion KRW | 68.45% |
| 2019 | 365.28 Billion KRW | 68.29% |
| 2018 | 217.06 Billion KRW | 37.14% |
| 2017 | 158.27 Billion KRW | 22.99% |
| 2016 | 128.69 Billion KRW | 51.01% |
| 2015 | 85.22 Billion KRW | 0.46% |
| 2014 | 84.82 Billion KRW | 8.39% |
| 2013 | 78.25 Billion KRW | -15.93% |
| 2012 | 93.08 Billion KRW | -19.99% |
| 2011 | 116.33 Billion KRW | 47.82% |
| 2010 | 78.69 Billion KRW | 33.24% |
| 2009 | 59.06 Billion KRW | 86.87% |
| 2008 | 31.6 Billion KRW | 1.85% |
| 2007 | 31.03 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 610.82 Billion KRW | 2.51% |
| 2024 Q1 | 595.85 Billion KRW | 1.1% |
| 2023 Q3 | 744.89 Billion KRW | 7.24% |
| 2023 Q2 | 694.62 Billion KRW | 1.76% |
| 2023 FY | 589.39 Billion KRW | -12.82% |
| 2023 Q1 | 682.58 Billion KRW | 0.96% |
| 2023 Q4 | 589.39 Billion KRW | -20.88% |
| 2022 Q1 | 617.76 Billion KRW | 0.51% |
| 2022 FY | 676.1 Billion KRW | 10.0% |
| 2022 Q4 | 676.1 Billion KRW | 7.36% |
| 2022 Q3 | 629.75 Billion KRW | 1.84% |
| 2022 Q2 | 618.34 Billion KRW | 0.09% |
| 2021 FY | 614.62 Billion KRW | -0.11% |
| 2021 Q4 | 614.62 Billion KRW | 0.57% |
| 2021 Q1 | 611.98 Billion KRW | -0.54% |
| 2021 Q2 | 612.58 Billion KRW | 0.1% |
| 2021 Q3 | 611.14 Billion KRW | -0.24% |
| 2020 FY | 615.3 Billion KRW | 68.45% |
| 2020 Q4 | 615.3 Billion KRW | -0.32% |
| 2020 Q3 | 617.3 Billion KRW | 65.31% |
| 2020 Q1 | 376.44 Billion KRW | 3.06% |
| 2020 Q2 | 373.42 Billion KRW | -0.8% |
| 2019 Q2 | 199.11 Billion KRW | 1.15% |
| 2019 Q4 | 365.28 Billion KRW | -3.69% |
| 2019 FY | 365.28 Billion KRW | 68.29% |
| 2019 Q1 | 196.84 Billion KRW | -9.31% |
| 2019 Q3 | 379.27 Billion KRW | 90.48% |
| 2018 Q2 | 217.68 Billion KRW | 38.92% |
| 2018 Q3 | 219.74 Billion KRW | 0.95% |
| 2018 FY | 217.06 Billion KRW | 37.14% |
| 2018 Q4 | 217.06 Billion KRW | -1.22% |
| 2018 Q1 | 156.69 Billion KRW | -1.0% |
| 2017 Q4 | 158.27 Billion KRW | -6.14% |
| 2017 FY | 158.27 Billion KRW | 22.99% |
| 2017 Q3 | 168.63 Billion KRW | 34.65% |
| 2017 Q2 | 125.23 Billion KRW | -4.21% |
| 2017 Q1 | 130.74 Billion KRW | 1.6% |
| 2016 FY | 128.69 Billion KRW | 51.01% |
| 2016 Q2 | 128.74 Billion KRW | 22.55% |
| 2016 Q3 | 128.19 Billion KRW | -0.43% |
| 2016 Q4 | 128.69 Billion KRW | 0.39% |
| 2016 Q1 | 105.05 Billion KRW | 23.27% |
| 2015 Q3 | 84.37 Billion KRW | 0.25% |
| 2015 Q4 | 85.22 Billion KRW | 1.0% |
| 2015 Q1 | 86.28 Billion KRW | 1.71% |
| 2015 Q2 | 84.17 Billion KRW | -2.45% |
| 2015 FY | 85.22 Billion KRW | 0.46% |
| 2014 Q2 | 82.76 Billion KRW | -5.22% |
| 2014 Q1 | 87.32 Billion KRW | 11.59% |
| 2014 FY | 84.82 Billion KRW | 8.39% |
| 2014 Q4 | 84.82 Billion KRW | -1.95% |
| 2014 Q3 | 86.51 Billion KRW | 4.53% |
| 2013 Q4 | 78.25 Billion KRW | 2.35% |
| 2013 FY | 78.25 Billion KRW | -15.93% |
| 2013 Q3 | 76.46 Billion KRW | -1.02% |
| 2013 Q2 | 77.25 Billion KRW | -7.11% |
| 2013 Q1 | 83.17 Billion KRW | -10.65% |
| 2012 FY | 93.08 Billion KRW | -19.99% |
| 2012 Q4 | 93.08 Billion KRW | 0.0% |
| 2012 Q1 | 107.81 Billion KRW | 0.0% |
| 2011 Q1 | 83.15 Billion KRW | 0.0% |
| 2011 FY | 116.33 Billion KRW | 47.82% |
| 2011 Q3 | 96.11 Billion KRW | 15.47% |
| 2011 Q2 | 83.24 Billion KRW | 0.1% |
| 2010 Q1 | 58.75 Billion KRW | -0.18% |
| 2010 FY | 78.69 Billion KRW | 33.24% |
| 2010 Q2 | 65.37 Billion KRW | 11.27% |
| 2009 Q4 | 58.85 Billion KRW | 0.0% |
| 2009 FY | 59.06 Billion KRW | 86.87% |
| 2009 Q2 | 52.07 Billion KRW | 63.48% |
| 2009 Q1 | 31.85 Billion KRW | 17.58% |
| 2008 FY | 31.6 Billion KRW | 1.85% |
| 2008 Q2 | 31.4 Billion KRW | -11.32% |
| 2008 Q1 | 35.41 Billion KRW | 23.18% |
| 2008 Q4 | 27.09 Billion KRW | 0.0% |
| 2007 Q1 | 26.17 Billion KRW | 0.0% |
| 2007 Q2 | 27.01 Billion KRW | 3.22% |
| 2007 FY | 31.03 Billion KRW | 0.0% |
| 2007 Q4 | 28.75 Billion KRW | -7.35% |
| 2007 Q3 | 31.03 Billion KRW | 14.88% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -197.354% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 69.884% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 32.794% |
| HANDOK Inc. | 790.33 Billion KRW | 25.425% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -245.444% |
| Yuhan Corporation | 2814.07 Billion KRW | 79.055% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 55.186% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -530.512% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 69.806% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -145.841% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -25.697% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -412.638% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -149.165% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -69.179% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -197.354% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -40.604% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -17.932% |
| JW Holdings Corporation | 1176.26 Billion KRW | 49.893% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 3.577% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 57.973% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 8.626% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -68.359% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -282.623% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -59.004% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -20.945% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -197.354% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 45.328% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 66.707% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 8.626% |
| Yuhan Corporation | 2814.07 Billion KRW | 79.055% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 33.023% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -160.103% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 40.689% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 8.626% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -40.366% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -25.708% |
| CKD Bio Corp. | 293.78 Billion KRW | -100.622% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -16.023% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -4.323% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -46.899% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -68.359% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 59.52% |
| Boryung Corporation | 922.36 Billion KRW | 36.099% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -33.208% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -25.697% |
| JW Lifescience Corporation | 255.83 Billion KRW | -130.38% |